Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117206) titled 'A Phase II Clinical Study of Sequential Iparomlimab and Tuvonralimab Combined with Chemotherapy Following Local Radiotherapy in Breast Cancer Patients with Poor Response to Neoadjuvant Chemotherapy' on Jan. 21.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The Fourth Hospital of Hebei Medical University
Condition:
Breast cancer
Intervention:
Triat group:1. Neoadjuvant chemotherapy phase:
(1) Hormone receptor-positive patients: TA regimen (nab-paclitaxel 125 mg/m^2 + epirubicin 75-100 mg/m^2, q3w, day 1, for 3 cycles)
(2) Triple-negative breast cancer patients: TP regimen (nab-...